- Home
- EWCZ vs MGNX Comparison
EWCZ vs MGNX Comparison
Compare EWCZ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- MGNX
- Stock Information
- Founded
- EWCZ 2004
- MGNX 2000
- Country
- EWCZ United States
- MGNX United States
- Employees
- EWCZ N/A
- MGNX N/A
- Industry
- EWCZ Package Goods/Cosmetics
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- MGNX Health Care
- Exchange
- EWCZ Nasdaq
- MGNX Nasdaq
- Market Cap
- EWCZ 294.0M
- MGNX 257.3M
- IPO Year
- EWCZ 2021
- MGNX 2013
- Fundamental
- Price
- EWCZ $5.89
- MGNX $3.24
- Analyst Decision
- EWCZ Buy
- MGNX Buy
- Analyst Count
- EWCZ 7
- MGNX 11
- Target Price
- EWCZ $7.64
- MGNX $8.57
- AVG Volume (30 Days)
- EWCZ 755.4K
- MGNX 770.4K
- Earning Date
- EWCZ 11-14-2024
- MGNX 11-05-2024
- Dividend Yield
- EWCZ N/A
- MGNX N/A
- EPS Growth
- EWCZ 62.57
- MGNX N/A
- EPS
- EWCZ 0.23
- MGNX N/A
- Revenue
- EWCZ $223,500,000.00
- MGNX $141,329,000.00
- Revenue This Year
- EWCZ $0.81
- MGNX $119.63
- Revenue Next Year
- EWCZ $4.02
- MGNX N/A
- P/E Ratio
- EWCZ $25.61
- MGNX N/A
- Revenue Growth
- EWCZ 2.42
- MGNX 16.68
- 52 Week Low
- EWCZ $4.80
- MGNX $2.95
- 52 Week High
- EWCZ $16.07
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- EWCZ 37.35
- MGNX 37.79
- Support Level
- EWCZ $5.38
- MGNX $3.61
- Resistance Level
- EWCZ $6.14
- MGNX $5.10
- Average True Range (ATR)
- EWCZ 0.63
- MGNX 0.35
- MACD
- EWCZ -0.22
- MGNX -0.10
- Stochastic Oscillator
- EWCZ 14.46
- MGNX 4.62
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).